Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

A Rapid Allele-Specific Assay for HLA-A*32:01 to Identify Patients at Risk for Vancomycin-Induced Drug Reaction with Eosinophilia and Systemic Symptoms.

Rwandamuriye FX, Chopra A, Konvinse KC, Choo L, Trubiano JA, Shaffer CM, Watson M, Mallal SA, Phillips EJ.

J Mol Diagn. 2019 May 31. pii: S1525-1578(19)30076-5. doi: 10.1016/j.jmoldx.2019.04.006. [Epub ahead of print]

PMID:
31158526
2.

Widespread Tau-Specific CD4 T Cell Reactivity in the General Population.

Lindestam Arlehamn CS, Pham J, Alcalay RN, Frazier A, Shorr E, Carpenter C, Sidney J, Dhanwani R, Agin-Liebes J, Garretti F, Amara AW, Standaert DG, Phillips EJ, Mallal SA, Peters B, Sulzer D, Sette A.

J Immunol. 2019 Jul 1;203(1):84-92. doi: 10.4049/jimmunol.1801506. Epub 2019 May 13.

PMID:
31085590
3.

Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance.

Wanjalla CN, McDonnell WJ, Barnett L, Simmons JD, Furch BD, Lima MC, Woodward BO, Fan R, Fei Y, Baker PG, Ram R, Pilkinton MA, Mashayekhi M, Brown NJ, Mallal SA, Kalams SA, Koethe JR.

Front Immunol. 2019 Mar 19;10:408. doi: 10.3389/fimmu.2019.00408. eCollection 2019.

4.

Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Tian Y, Babor M, Lane J, Seumois G, Liang S, Goonawardhana NDS, De Silva AD, Phillips EJ, Mallal SA, da Silva Antunes R, Grifoni A, Vijayanand P, Weiskopf D, Peters B, Sette A.

J Clin Invest. 2019 Mar 18;130:1727-1741. doi: 10.1172/JCI123726. eCollection 2019 Mar 18.

5.

HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.

Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, Schutte RJ, Ostrov DA, Pilkinton MA, Rosenbach M, Zwerner JP, Williams KB, Bourke J, Martinez P, Rwandamuriye F, Chopra A, Watson M, Redwood AJ, White KD, Mallal SA, Phillips EJ.

J Allergy Clin Immunol. 2019 Jul;144(1):183-192. doi: 10.1016/j.jaci.2019.01.045. Epub 2019 Feb 16.

PMID:
30776417
6.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
7.

High CD8 T-Cell Receptor Clonality and Altered CDR3 Properties Are Associated With Elevated Isolevuglandins in Adipose Tissue During Diet-Induced Obesity.

McDonnell WJ, Koethe JR, Mallal SA, Pilkinton MA, Kirabo A, Ameka MK, Cottam MA, Hasty AH, Kennedy AJ.

Diabetes. 2018 Nov;67(11):2361-2376. doi: 10.2337/db18-0040. Epub 2018 Sep 4.

8.

Applications of Immunopharmacogenomics: Predicting, Preventing, and Understanding Immune-Mediated Adverse Drug Reactions.

Karnes JH, Miller MA, White KD, Konvinse KC, Pavlos RK, Redwood AJ, Peter JG, Lehloenya R, Mallal SA, Phillips EJ.

Annu Rev Pharmacol Toxicol. 2019 Jan 6;59:463-486. doi: 10.1146/annurev-pharmtox-010818-021818. Epub 2018 Aug 22.

9.

Multi-Donor Longitudinal Antibody Repertoire Sequencing Reveals the Existence of Public Antibody Clonotypes in HIV-1 Infection.

Setliff I, McDonnell WJ, Raju N, Bombardi RG, Murji AA, Scheepers C, Ziki R, Mynhardt C, Shepherd BE, Mamchak AA, Garrett N, Karim SA, Mallal SA, Crowe JE Jr, Morris L, Georgiev IS.

Cell Host Microbe. 2018 Jun 13;23(6):845-854.e6. doi: 10.1016/j.chom.2018.05.001. Epub 2018 May 31.

10.

Active suppression rather than ignorance: tolerance to abacavir-induced HLA-B*57:01 peptide repertoire alteration.

Phillips EJ, Mallal SA.

J Clin Invest. 2018 Jul 2;128(7):2746-2749. doi: 10.1172/JCI121525. Epub 2018 May 21.

11.

Weaker HLA Footprints on HIV in the Unique and Highly Genetically Admixed Host Population of Mexico.

Soto-Nava M, Avila-Ríos S, Valenzuela-Ponce H, García-Morales C, Carlson JM, Tapia-Trejo D, Garrido-Rodriguez D, Alva-Hernández SN, García-Tellez TA, Murakami-Ogasawara A; International HIV Adaptation Collaborative, Mallal SA, John M, Brockman MA, Brumme CJ, Brumme ZL, Reyes-Teran G; HIV MexNet Group.

J Virol. 2018 Jan 2;92(2). pii: e01128-17. doi: 10.1128/JVI.01128-17. Print 2018 Jan 15.

12.

Cytomegalovirus (CMV) Epitope-Specific CD4+ T Cells Are Inflated in HIV+ CMV+ Subjects.

Abana CO, Pilkinton MA, Gaudieri S, Chopra A, McDonnell WJ, Wanjalla C, Barnett L, Gangula R, Hager C, Jung DK, Engelhardt BG, Jagasia MH, Klenerman P, Phillips EJ, Koelle DM, Kalams SA, Mallal SA.

J Immunol. 2017 Nov 1;199(9):3187-3201. doi: 10.4049/jimmunol.1700851. Epub 2017 Oct 2.

13.

Severe Delayed Drug Reactions: Role of Genetics and Viral Infections.

Pavlos R, White KD, Wanjalla C, Mallal SA, Phillips EJ.

Immunol Allergy Clin North Am. 2017 Nov;37(4):785-815. doi: 10.1016/j.iac.2017.07.007. Review.

14.

HLA Class I and II alleles, heterozygosity and HLA-KIR interactions are associated with rates of genital HSV shedding and lesions.

Magaret A, Dong L, John M, Mallal SA, James I, Warren T, Gaudieri S, Koelle DM, Wald A.

Genes Immun. 2016 Dec;17(7):412-418. doi: 10.1038/gene.2016.42. Epub 2016 Nov 17.

15.

Homeostatic Responses Regulate Selfish Mitochondrial Genome Dynamics in C. elegans.

Gitschlag BL, Kirby CS, Samuels DC, Gangula RD, Mallal SA, Patel MR.

Cell Metab. 2016 Jul 12;24(1):91-103. doi: 10.1016/j.cmet.2016.06.008.

16.

CD70 Exacerbates Blood Pressure Elevation and Renal Damage in Response to Repeated Hypertensive Stimuli.

Itani HA, Xiao L, Saleh MA, Wu J, Pilkinton MA, Dale BL, Barbaro NR, Foss JD, Kirabo A, Montaniel KR, Norlander AE, Chen W, Sato R, Navar LG, Mallal SA, Madhur MS, Bernstein KE, Harrison DG.

Circ Res. 2016 Apr 15;118(8):1233-43. doi: 10.1161/CIRCRESAHA.115.308111. Epub 2016 Mar 17.

17.

Extensive CD4 and CD8 T Cell Cross-Reactivity between Alphaherpesviruses.

Jing L, Laing KJ, Dong L, Russell RM, Barlow RS, Haas JG, Ramchandani MS, Johnston C, Buus S, Redwood AJ, White KD, Mallal SA, Phillips EJ, Posavad CM, Wald A, Koelle DM.

J Immunol. 2016 Mar 1;196(5):2205-2218. doi: 10.4049/jimmunol.1502366. Epub 2016 Jan 25.

18.

The evolving story of human leukocyte antigen and the immunogenetics of peanut allergy.

Hemler JA, Phillips EJ, Mallal SA, Kendall PL.

Ann Allergy Asthma Immunol. 2015 Dec;115(6):471-6. doi: 10.1016/j.anai.2015.10.008. Epub 2015 Oct 27. Review.

19.

RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2016 Mar 15;22(6):1499-509. doi: 10.1158/1078-0432.CCR-15-1125. Epub 2015 Oct 29. Erratum in: Clin Cancer Res. 2019 Feb 15;25(4):1437.

20.

Prostaglandin I2 Signaling and Inhibition of Group 2 Innate Lymphoid Cell Responses.

Zhou W, Toki S, Zhang J, Goleniewksa K, Newcomb DC, Cephus JY, Dulek DE, Bloodworth MH, Stier MT, Polosuhkin V, Gangula RD, Mallal SA, Broide DH, Peebles RS Jr.

Am J Respir Crit Care Med. 2016 Jan 1;193(1):31-42. doi: 10.1164/rccm.201410-1793OC.

21.

Report from the National Institute of Allergy and Infectious Diseases workshop on drug allergy.

Wheatley LM, Plaut M, Schwaninger JM, Banerji A, Castells M, Finkelman FD, Gleich GJ, Guttman-Yassky E, Mallal SA, Naisbitt DJ, Ostrov DA, Phillips EJ, Pichler WJ, Platts-Mills TA, Roujeau JC, Schwartz LB, Trepanier LA.

J Allergy Clin Immunol. 2015 Aug;136(2):262-71.e2. doi: 10.1016/j.jaci.2015.05.027.

22.

Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa.

Phillips E, Bartlett JA, Sanne I, Lederman MM, Hinkle J, Rousseau F, Dunn D, Pavlos R, James I, Mallal SA, Haas DW.

J Acquir Immune Defic Syndr. 2013 Feb 1;62(2):e55-7. doi: 10.1097/QAI.0b013e31827ca50f. No abstract available.

23.

HLA-B*5701 and flucloxacillin associated drug-induced liver disease.

Phillips EJ, Mallal SA.

AIDS. 2013 Jan 28;27(3):491-2. doi: 10.1097/QAD.0b013e32835ca9d5. No abstract available.

PMID:
23291545
24.

Viral adaptation to host immune responses occurs in chronic hepatitis B virus (HBV) infection, and adaptation is greatest in HBV e antigen-negative disease.

Desmond CP, Gaudieri S, James IR, Pfafferott K, Chopra A, Lau GK, Audsley J, Day C, Chivers S, Gordon A, Revill PA, Bowden S, Ayres A, Desmond PV, Thompson AJ, Roberts SK, Locarnini SA, Mallal SA, Lewin SR.

J Virol. 2012 Jan;86(2):1181-92. doi: 10.1128/JVI.05308-11. Epub 2011 Nov 9.

25.

HLA-B*1502 screening and toxic effects of carbamazepine.

Phillips EJ, Mallal SA.

N Engl J Med. 2011 Aug 18;365(7):672; author reply 673. doi: 10.1056/NEJMc1105467. No abstract available.

PMID:
21848472
26.

Drug hypersensitivity: pharmacogenetics and clinical syndromes.

Phillips EJ, Chung WH, Mockenhaupt M, Roujeau JC, Mallal SA.

J Allergy Clin Immunol. 2011 Mar;127(3 Suppl):S60-6. doi: 10.1016/j.jaci.2010.11.046.

27.

Pharmacogenetics of drug hypersensitivity.

Phillips EJ, Mallal SA.

Pharmacogenomics. 2010 Jul;11(7):973-87. doi: 10.2217/pgs.10.77. Review.

28.

Personalizing antiretroviral therapy: is it a reality?

Phillips EJ, Mallal SA.

Per Med. 2009 Jul;6(4):393-408. doi: 10.2217/pme.09.12.

PMID:
29783545
29.

HLA and drug-induced toxicity.

Phillips EJ, Mallal SA.

Curr Opin Mol Ther. 2009 Jun;11(3):231-42.

PMID:
19479656
30.

Pharmacogenetics and the potential for the individualization of antiretroviral therapy.

Phillips EJ, Mallal SA.

Curr Opin Infect Dis. 2008 Feb;21(1):16-24. doi: 10.1097/QCO.0b013e3282f42224. Review.

PMID:
18192781
31.

Evidence of viral adaptation to HLA class I-restricted immune pressure in chronic hepatitis C virus infection.

Gaudieri S, Rauch A, Park LP, Freitas E, Herrmann S, Jeffrey G, Cheng W, Pfafferott K, Naidoo K, Chapman R, Battegay M, Weber R, Telenti A, Furrer H, James I, Lucas M, Mallal SA.

J Virol. 2006 Nov;80(22):11094-104. Erratum in: J Virol. 2007 Aug;81(16):8846-8.

32.

Tissue-specific associations between mitochondrial DNA levels and current treatment status in HIV-infected individuals.

Cherry CL, Nolan D, James IR, McKinnon EJ, Mallal SA, Gahan ME, Lal L, McArthur JC, Wesselingh SL.

J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):435-40.

PMID:
16810110
33.

Selective escape from CD8+ T-cell responses represents a major driving force of human immunodeficiency virus type 1 (HIV-1) sequence diversity and reveals constraints on HIV-1 evolution.

Allen TM, Altfeld M, Geer SC, Kalife ET, Moore C, O'sullivan KM, Desouza I, Feeney ME, Eldridge RL, Maier EL, Kaufmann DE, Lahaie MP, Reyor L, Tanzi G, Johnston MN, Brander C, Draenert R, Rockstroh JK, Jessen H, Rosenberg ES, Mallal SA, Walker BD.

J Virol. 2005 Nov;79(21):13239-49.

34.

De novo generation of escape variant-specific CD8+ T-cell responses following cytotoxic T-lymphocyte escape in chronic human immunodeficiency virus type 1 infection.

Allen TM, Yu XG, Kalife ET, Reyor LL, Lichterfeld M, John M, Cheng M, Allgaier RL, Mui S, Frahm N, Alter G, Brown NV, Johnston MN, Rosenberg ES, Mallal SA, Brander C, Walker BD, Altfeld M.

J Virol. 2005 Oct;79(20):12952-60.

35.

Killer immunoglobulin-like receptors and HLA act both independently and synergistically to modify HIV disease progression.

Gaudieri S, DeSantis D, McKinnon E, Moore C, Nolan D, Witt CS, Mallal SA, Christiansen FT.

Genes Immun. 2005 Dec;6(8):683-90.

PMID:
16121209
36.

Interactive selective pressures of HLA-restricted immune responses and antiretroviral drugs on HIV-1.

John M, Moore CB, James IR, Mallal SA.

Antivir Ther. 2005;10(4):551-5.

PMID:
16038481
37.

Clinical and immunogenetic correlates of abacavir hypersensitivity.

Phillips EJ, Wong GA, Kaul R, Shahabi K, Nolan DA, Knowles SR, Martin AM, Mallal SA, Shear NH.

AIDS. 2005 Jun 10;19(9):979-81.

PMID:
15905681
38.

Iatrogenic Cushing's syndrome in an HIV-infected patient treated with ritonavir and inhaled fluticasone.

Gillett MJ, Cameron PU, Nguyen HV, Hurley DM, Mallal SA.

AIDS. 2005 Apr 29;19(7):740-1. No abstract available.

PMID:
15821405
39.

Selection, transmission, and reversion of an antigen-processing cytotoxic T-lymphocyte escape mutation in human immunodeficiency virus type 1 infection.

Allen TM, Altfeld M, Yu XG, O'Sullivan KM, Lichterfeld M, Le Gall S, John M, Mothe BR, Lee PK, Kalife ET, Cohen DE, Freedberg KA, Strick DA, Johnston MN, Sette A, Rosenberg ES, Mallal SA, Goulder PJ, Brander C, Walker BD.

J Virol. 2004 Jul;78(13):7069-78.

40.

Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients.

Pace CS, Martin AM, Hammond EL, Mamotte CD, Nolan DA, Mallal SA.

Antivir Ther. 2003 Aug;8(4):323-31.

PMID:
14518702
41.

Randomized, controlled, 48-week study of switching stavudine and/or protease inhibitors to combivir/abacavir to prevent or reverse lipoatrophy in HIV-infected patients.

John M, McKinnon EJ, James IR, Nolan DA, Herrmann SE, Moore CB, White AJ, Mallal SA.

J Acquir Immune Defic Syndr. 2003 May 1;33(1):29-33.

PMID:
12792352
42.

Viral load detectability profiles for HIV infection.

McKinnon EJ, James IR, John M, Mallal SA.

Stat Med. 2003 Feb 15;22(3):385-96.

PMID:
12529870
43.

Evidence of HIV-1 adaptation to HLA-restricted immune responses at a population level.

Moore CB, John M, James IR, Christiansen FT, Witt CS, Mallal SA.

Science. 2002 May 24;296(5572):1439-43.

44.

Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.

French MA, Lenzo N, John M, Mallal SA, McKinnon EJ, James IR, Price P, Flexman JP, Tay-Kearney ML.

HIV Med. 2000 Mar;1(2):107-15.

45.

Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3'A alleles on HIV-1 disease progression: An international meta-analysis of individual-patient data.

Ioannidis JP, Rosenberg PS, Goedert JJ, Ashton LJ, Benfield TL, Buchbinder SP, Coutinho RA, Eugen-Olsen J, Gallart T, Katzenstein TL, Kostrikis LG, Kuipers H, Louie LG, Mallal SA, Margolick JB, Martinez OP, Meyer L, Michael NL, Operskalski E, Pantaleo G, Rizzardi GP, Schuitemaker H, Sheppard HW, Stewart GJ, Theodorou ID, Ullum H, Vicenzi E, Vlahov D, Wilkinson D, Workman C, Zagury JF, O'Brien TR; International Meta-Analysis of HIV Host Genetics.

Ann Intern Med. 2001 Nov 6;135(9):782-95.

PMID:
11694103
46.

Chronic hyperlactatemia in HIV-infected patients taking antiretroviral therapy.

John M, Moore CB, James IR, Nolan D, Upton RP, McKinnon EJ, Mallal SA.

AIDS. 2001 Apr 13;15(6):717-23.

PMID:
11371686
47.

Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection.

Mallal SA, John M, Moore CB, James IR, McKinnon EJ.

AIDS. 2000 Jul 7;14(10):1309-16.

PMID:
10930144
48.
49.

The Western Australian HIV Cohort Study, Perth, Australia.

Mallal SA.

J Acquir Immune Defic Syndr Hum Retrovirol. 1998;17 Suppl 1:S23-7.

PMID:
9586648
50.

Trends in incidence of AIDS illnesses in Australia from 1983 to 1994: the Australian AIDS cohort.

Dore GJ, Hoy JF, Mallal SA, Li Y, Mijch AM, French MA, Cooper DA, Kaldor JM.

J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Sep 1;16(1):39-43.

PMID:
9377123

Supplemental Content

Loading ...
Support Center